Clinical Trial Detail

NCT ID NCT01911507
Title INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, Davis
Indications

lung non-small cell carcinoma

Therapies

Capmatinib + Erlotinib

Age Groups: adult senior

No variant requirements are available.